register

News & Trends - MedTech & Diagnostics

Westmead Private first in the state to implant neurosurgery medical device

Health Industry Hub | February 12, 2021 |

MedTech News: A medical device which is used to manage difficult-to-treat epilepsy is now available for the first time in a New South Wales private hospital.

Westmead Private Hospital has installed LivaNova’s most recent SenTiva Vagal Nerve Stimulator (VNS) in Australia, giving private patients access to treatment which was previously only available at one public hospital. 

The VNS is a device which is attached to a nerve in the neck and provides a current which may reduce the number of seizures a person experiences over time as well as improve the person’s overall quality of life. 

The device was implanted by Westmead Private Hospital neurosurgeon, Professor Mark Dexter, who is also Director of the Epilepsy Surgery Program at Westmead Health Precinct. 

Dr Michael Fong from Neurology New South Wales said giving patients access to neurostimulation at Westmead Private Hospital was a great milestone. 

“More than one-third of patients with epilepsy can’t control their condition with anti-seizure medications. For some of them, surgery may be an option but for many this is too risky or not possible for their epilepsy type,” Dr Fong said. 

You may also like Zimmer to spin off spine and dental business

“Neurostimulation can help reduce the abnormal electrical activity of the brain, which results in seizures, and the most established way of performing neurostimulation is a Vagal Nerve Stimulator.” 

“Not only has Westmead Private placed the first privately inserted VNS devices in New South Wales, it is also the first in Australia to utilise the most up-to-date technology in SenTiva.  This new device is only about the size of a 50 cent coin and is significantly smaller than previous models,” he said. 

Westmead Private Hospital’s SenTiva VNS also provides great benefit to regional patients looking to be fitted with the device, because they need fewer return visits to hospital for examination. 

Unlike previous models which required fortnightly to monthly check-ups with the patient, the SenTiva VNS allows the neurologist to determine up to three months therapy before they need to see the patient again. 

The SenTiva device also allows a different amount of therapy to be scheduled between night and day which can be invaluable in patients whose seizures occur predominantly at the same time.  


Human Resources

Medtronic HR Director deep dives into shifting workplaces and leadership trends: International HR Day

Medtronic HR Director deep dives into shifting workplaces and leadership trends: International HR Day

Health Industry Hub | May 20, 2024 |

People & Culture: Coinciding with International HR Day, Karen Newell, Senior HR Director for ANZ at Medtronic, joined Health Industry […]

More


News & Trends - MedTech & Diagnostics

Aussie medtech reveals new data on next-gen pulsed field ablation system for atrial fibrillation

Aussie medtech reveals new data on next-gen pulsed field ablation system for atrial fibrillation

Health Industry Hub | May 20, 2024 |

MedTech & Diagnostics News: An Australian-based medtech company announced promising results from the first-in-human study for its pulsed field ablation […]

More


News & Trends - MedTech & Diagnostics

Federal budget delivers 'mixed news' for radiologists

Federal budget delivers ‘mixed news’ for radiologists

Health Industry Hub | May 20, 2024 |

MedTech & Diagnostics News: The Royal College of Australian and New Zealand Radiologists (RANZCR) and the Interventional Radiology Society of […]

More


News & Trends - Pharmaceuticals

AstraZeneca, BMS and Noxopharm address findings of inquiry report into rare cancers

AstraZeneca, BMS and Noxopharm address findings of inquiry report into rare cancers

Health Industry Hub | May 20, 2024 |

Pharma News: The Senate Community Affairs References Committee has released its inquiry report into Equitable access to diagnosis and treatment […]

More


This content is copyright protected. Please subscribe to gain access.